Approaches to anemia management can differ between the US and Europe. In this video round table, recorded in late 2016 in Chicago, Drs Jay Wish, Steven Fishbane, and Kam Kalantar-Zadeh provide expert insights into best practices for anemia management in CKD patients.
The meeting has been divided into five short video segments, which you will find below, making them quick and easy to view:
Which of the guidelines for anemia management in CKD are followed most closely in the US?
What anemia treatment options would you consider in ND-CKD patients and why?
Who is treating anemia in ND CKD patients in the US? Does this vary with CKD stage?
What are the relevant biomarkers and threshold targets for iron management in the US?
Would you consider treating ID without anemia?
The panel discusses:
- The respective content of the KDIGO and KDOQI guidelines for anemia management, and which they feel is more closely followed by practitioners in the US
- Challenges in implementing best practice guidelines in the non-dialysis setting
- Therapy options for treating anemia in the non-dialysis population, and the importance of this treatment
- Best practices in nephrologist referrals from primary care
- The value of monitoring iron parameters as well as haemoglobin
- Acceptable thresholds for initiating anemia treatment and appropriate therapeutic targets
- The ideal frequency of anemia testing in non-dialysis CKD
- The benefits of treating iron deficiency without the presence of anemia, including potential cognitive and cardiovascular effects.
It’s not just improving anaemia, but it’s getting enough iron to the person for their basic health needs, for the ability to produce ATP, store energy and to be able to live a life with a quality of life that I think is important.– Professor Steven Fishbane
You don’t wait for them to get anaemic. You want to be sure that you’re up to date in terms of what their haemoglobin level and what their iron stores are.– Professor Jay Wish